VANCOUVER, BC, CANADA, July 10, 2023 (GLOBE NEWSWIRE) -- Jolt Health Inc. ("JOLT" and or "the Company") (CSE:JOLT) (FSE: G1Q0) announced as per CSE policy, that is intends to close its previously announced non-brokered private placement financing on July 15^th, 2023. The company will issue a total 6,984,266 units for gross proceeds of $100,125 at $0.0143 per unit. Each unit consists of one common share and one common share warrant. Each warrant entitles the holder to subscribe for one additional common share for a period of 2 years from the date of closing at a price of $0.05, subject to the Corporation's option to accelerate the expiry date if the stock trades at $0.15 for 10 trading days.

The company will pay finders fees of $1,125.25 and issue 87,500 brokers warrants in accordance with closing.

About Jolt Health Inc.

Jolt Health Inc. (CSE – JOLT) is a leading life sciences company focused on healthcare, biotechnology and artificial intelligence. The company currently holds exclusive licenses for innovative therapeutic and pharmaceutical products throughout Europe, the UK, and North America. The company is committed to transforming the industry through research, collaboration, and technological advancement, shaping the future of healthcare worldwide.

For further information, please contact:

Investor Relations

Telephone: 1 (604) 343-2977

E-mail: info@jolt-health.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company's business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.

CONTACT: Investor Relations Jolt Health Inc.  1 (604) 343-2977 investors@love-pharma.com